Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.JBIO · Entity 4757 | See Remarks | February 12, 2026 | February 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date February 12, 2026 · Filed February 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 386,113 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 41,250 · Balance 386,113 F1: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.81 · Expires 2036-02-11 | Direct | 247,500 |
Reported balance
After 2026-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-12 · Grant · Acquired 247,500 · Balance 247,500 F2: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 19,157 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2029-06-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 43,047 · Balance 0 F2: This stock option award, which provided for 25% of the award to vest on May 6, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2030-03-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 73,047 · Balance 0 F3: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 89,545 · Balance 0 F4: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.14 · Expires 2031-02-09 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-11 · Disposition to issuer · Disposed 60,000 · Balance 0 F5: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.59 · Expires 2031-06-06 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-11 · Disposition to issuer · Disposed 21,500 · Balance 0 F6: This stock option award, which provided for 25% of the award to vest on June 7, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.90 · Expires 2032-01-30 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-08-11 · Disposition to issuer · Disposed 100,000 · Balance 0 F7: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.27 · Expires 2033-01-30 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-08-11 · Disposition to issuer · Disposed 104,000 · Balance 0 F8: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-08-11 · Disposition to issuer · Disposed 10,152 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-08-11 · Disposition to issuer · Disposed 6,802 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-08-11 · Disposition to issuer · Disposed 16,667 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-08-11 · Disposition to issuer · Disposed 6,667 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F13: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-08-11 · Disposition to issuer · Disposed 26,000 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F14: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-08-11 · Disposition to issuer · Disposed 8,400 · Balance 0 F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F15: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: This stock option award, which provided for 25% of the award to vest on May 6, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F3: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F4: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F5: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F6: This stock option award, which provided for 25% of the award to vest on June 7, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F7: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F8: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F9: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F12: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F13: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F14: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F15: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2022 Filed Feb 11, 2022 17:26 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 2,500 | $0.35 | $875.00 |
DisclosureSEC source: 0001209191-22-008937 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 19:56 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 6,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009564 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,605 Underlying: Common Stock · 6,801 shares Expires 2024-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 19:56 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 6,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-009564 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 17:22 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock (RSU)(Common Stock) · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006443 · doc4.xml · derivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2025-01-31 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 17:22 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001209191-22-006443 · doc4.xml · derivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 31, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 19:59 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-21-064363 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,547 Underlying: Common Stock · 2,500 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 19:59 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 5,000 | $13.53 | $67,659.50 |
DisclosureSEC source: 0001209191-21-064363 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,094 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 19:59 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 2,500 | $0.35 | $875.00 |
DisclosureSEC source: 0001209191-21-064363 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 18:48 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 10,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060112 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,304 Underlying: Common Stock · 10,151 shares Expires 2030-10-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 18:48 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Tax withholdingCommon Stock | 3,557 | $12.37 | $43,995.11 |
DisclosureSEC source: 0001209191-21-060112 · doc4.xml · nonDerivative · entry 2 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,594 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 18:48 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 10,151 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060112 · doc4.xml · nonDerivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 18:14 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantEmployee Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $17.59 | $0.00 |
DisclosureSEC source: 0001209191-21-039258 · doc4.xml · derivative · entry 1 King Andrew James · CIK 0001823187 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2031-06-06 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on June 7, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 18:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock (RSU)(Common Stock) · Derivative | 20,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010387 · doc4.xml · derivative · entry 2 King Andrew James · CIK 0001823187 · Head of Renal Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,406 Underlying: Common Stock · 20,406 shares Expires 2024-02-10 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 18:11 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $15.14 | $0.00 |
DisclosureSEC source: 0001209191-21-010387 · doc4.xml · derivative · entry 1 King Andrew James · CIK 0001823187 · Head of Renal Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 10, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 21:01 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantRestricted Stock Units (RSU)(Common Stock) · Derivative | 30,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054247 · doc4.xml · derivative · entry 4 King Andrew James · CIK 0001823187 · Head of Renal Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,455 Underlying: Common Stock · 30,455 shares Expires 2030-10-05 F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F7 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 21:01 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 89,545 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001209191-20-054247 · doc4.xml · derivative · entry 3 King Andrew James · CIK 0001823187 · Head of Renal Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,545 Underlying: Common Stock · 89,545 shares Expires 2030-10-05 F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on October 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 05, 2020 Filed Oct 7, 2020 21:01 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 73,047 | Not disclosed Strike: $0.42 | Not disclosed |
DisclosureSEC source: 0001209191-20-054247 · doc4.xml · derivative · entry 2 King Andrew James · CIK 0001823187 · Head of Renal Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,047 Underlying: Common Stock · 73,047 shares Expires 2030-03-18 F4 · price: Received in connection with the Merger in exchange for a stock option to acquire 250,000 shares of Private Chinook common stock for $0.12 per share. F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 05, 2020 Filed Oct 7, 2020 21:01 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 73,047 | Not disclosed Strike: $0.35 | Not disclosed |
DisclosureSEC source: 0001209191-20-054247 · doc4.xml · derivative · entry 1 King Andrew James · CIK 0001823187 · Head of Renal Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,047 Underlying: Common Stock · 73,047 shares Expires 2029-06-05 F2 · price: Received in connection with the merger of Private Chinook into the Issuer (the "Merger") in exchange for a stock option to acquire 250,000 shares of Private Chinook common stock for $0.10 per share. F1 · derivative.exercise_date: The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.